G Medical Innovations Holdings Ltd
G Medical Innovations Holdings Ltd (GMVD) Stock Competitors & Peer Comparison
See (GMVD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GMVD | $0.18 | +1.38% | 1.8M | -0.01 | -$18.76 | N/A |
| ISRG | $490.18 | -1.87% | 179B | 63.88 | $7.89 | N/A |
| BDX | $184.94 | +1.35% | 67.2B | 30.29 | $6.12 | +1.78% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +1.78% |
| ALC | $82.88 | -0.41% | 40.9B | 39.35 | $2.10 | +0.41% |
| MDLN | $49.99 | +5.02% | 40.4B | 72.17 | $0.69 | N/A |
| RMD | $261.01 | +1.84% | 37.8B | 25.66 | $10.10 | +0.90% |
| WST | $245.15 | +0.54% | 17.4B | 35.48 | $6.80 | +0.36% |
| HOLX | $75.44 | +0.39% | 16.8B | 31.30 | $2.41 | N/A |
| COO | $82.27 | -1.68% | 16.7B | 44.96 | $1.87 | N/A |
Stock Comparison
GMVD vs ISRG Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ISRG has a market cap of 179B. Regarding current trading prices, GMVD is priced at $0.18, while ISRG trades at $490.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ISRG's P/E ratio is 63.88. In terms of profitability, GMVD's ROE is +2.09%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, GMVD is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ISRG's competition here
GMVD vs BDX Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, BDX has a market cap of 67.2B. Regarding current trading prices, GMVD is priced at $0.18, while BDX trades at $184.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas BDX's P/E ratio is 30.29. In terms of profitability, GMVD's ROE is +2.09%, compared to BDX's ROE of +0.07%. Regarding short-term risk, GMVD is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check BDX's competition here
GMVD vs BDXA Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, GMVD is priced at $0.18, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas BDXA's P/E ratio is 21.44. In terms of profitability, GMVD's ROE is +2.09%, compared to BDXA's ROE of +0.07%. Regarding short-term risk, GMVD is more volatile compared to BDXA. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check BDXA's competition here
GMVD vs ALC Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ALC has a market cap of 40.9B. Regarding current trading prices, GMVD is priced at $0.18, while ALC trades at $82.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ALC's P/E ratio is 39.35. In terms of profitability, GMVD's ROE is +2.09%, compared to ALC's ROE of +0.05%. Regarding short-term risk, GMVD is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ALC's competition here
GMVD vs MDLN Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, MDLN has a market cap of 40.4B. Regarding current trading prices, GMVD is priced at $0.18, while MDLN trades at $49.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas MDLN's P/E ratio is 72.17. In terms of profitability, GMVD's ROE is +2.09%, compared to MDLN's ROE of +0.08%. Regarding short-term risk, GMVD is more volatile compared to MDLN. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check MDLN's competition here
GMVD vs RMD Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, RMD has a market cap of 37.8B. Regarding current trading prices, GMVD is priced at $0.18, while RMD trades at $261.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas RMD's P/E ratio is 25.66. In terms of profitability, GMVD's ROE is +2.09%, compared to RMD's ROE of +0.25%. Regarding short-term risk, GMVD is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check RMD's competition here
GMVD vs WST Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, WST has a market cap of 17.4B. Regarding current trading prices, GMVD is priced at $0.18, while WST trades at $245.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas WST's P/E ratio is 35.48. In terms of profitability, GMVD's ROE is +2.09%, compared to WST's ROE of +0.17%. Regarding short-term risk, GMVD is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check WST's competition here
GMVD vs HOLX Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, HOLX has a market cap of 16.8B. Regarding current trading prices, GMVD is priced at $0.18, while HOLX trades at $75.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas HOLX's P/E ratio is 31.30. In terms of profitability, GMVD's ROE is +2.09%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, GMVD is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check HOLX's competition here
GMVD vs COO Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, COO has a market cap of 16.7B. Regarding current trading prices, GMVD is priced at $0.18, while COO trades at $82.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas COO's P/E ratio is 44.96. In terms of profitability, GMVD's ROE is +2.09%, compared to COO's ROE of +0.05%. Regarding short-term risk, GMVD is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check COO's competition here
GMVD vs BDXB Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, GMVD is priced at $0.18, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas BDXB's P/E ratio is 7.60. In terms of profitability, GMVD's ROE is +2.09%, compared to BDXB's ROE of +0.07%. Regarding short-term risk, GMVD is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check BDXB's competition here
GMVD vs BAX Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, BAX has a market cap of 11.1B. Regarding current trading prices, GMVD is priced at $0.18, while BAX trades at $21.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas BAX's P/E ratio is -12.33. In terms of profitability, GMVD's ROE is +2.09%, compared to BAX's ROE of -0.12%. Regarding short-term risk, GMVD is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check BAX's competition here
GMVD vs ATR Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ATR has a market cap of 9.5B. Regarding current trading prices, GMVD is priced at $0.18, while ATR trades at $145.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ATR's P/E ratio is 24.63. In terms of profitability, GMVD's ROE is +2.09%, compared to ATR's ROE of +0.15%. Regarding short-term risk, GMVD is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ATR's competition here
GMVD vs MASI Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, GMVD is priced at $0.18, while MASI trades at $175.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas MASI's P/E ratio is -38.48. In terms of profitability, GMVD's ROE is +2.09%, compared to MASI's ROE of -0.59%. Regarding short-term risk, GMVD is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check MASI's competition here
GMVD vs RGEN Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, RGEN has a market cap of 7.6B. Regarding current trading prices, GMVD is priced at $0.18, while RGEN trades at $134.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas RGEN's P/E ratio is 13568.00. In terms of profitability, GMVD's ROE is +2.09%, compared to RGEN's ROE of +0.00%. Regarding short-term risk, GMVD is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check RGEN's competition here
GMVD vs BLCO Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, BLCO has a market cap of 6.4B. Regarding current trading prices, GMVD is priced at $0.18, while BLCO trades at $17.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas BLCO's P/E ratio is -20.87. In terms of profitability, GMVD's ROE is +2.09%, compared to BLCO's ROE of -0.06%. Regarding short-term risk, GMVD is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check BLCO's competition here
GMVD vs AVTR Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, AVTR has a market cap of 6.1B. Regarding current trading prices, GMVD is priced at $0.18, while AVTR trades at $8.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas AVTR's P/E ratio is -11.56. In terms of profitability, GMVD's ROE is +2.09%, compared to AVTR's ROE of -0.09%. Regarding short-term risk, GMVD is more volatile compared to AVTR. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check AVTR's competition here
GMVD vs TFX Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, TFX has a market cap of 5.1B. Regarding current trading prices, GMVD is priced at $0.18, while TFX trades at $112.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas TFX's P/E ratio is -16.11. In terms of profitability, GMVD's ROE is +2.09%, compared to TFX's ROE of -0.08%. Regarding short-term risk, GMVD is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check TFX's competition here
GMVD vs MMSI Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, MMSI has a market cap of 4.9B. Regarding current trading prices, GMVD is priced at $0.18, while MMSI trades at $81.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas MMSI's P/E ratio is 42.16. In terms of profitability, GMVD's ROE is +2.09%, compared to MMSI's ROE of +0.08%. Regarding short-term risk, GMVD is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check MMSI's competition here
GMVD vs STVN Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, STVN has a market cap of 4.4B. Regarding current trading prices, GMVD is priced at $0.18, while STVN trades at $16.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas STVN's P/E ratio is 26.72. In terms of profitability, GMVD's ROE is +2.09%, compared to STVN's ROE of +0.10%. Regarding short-term risk, GMVD is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check STVN's competition here
GMVD vs ICUI Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, GMVD is priced at $0.18, while ICUI trades at $152.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ICUI's P/E ratio is -506.55. In terms of profitability, GMVD's ROE is +2.09%, compared to ICUI's ROE of +0.00%. Regarding short-term risk, GMVD is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ICUI's competition here
GMVD vs WRBY Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, WRBY has a market cap of 2.9B. Regarding current trading prices, GMVD is priced at $0.18, while WRBY trades at $22.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas WRBY's P/E ratio is -296.37. In terms of profitability, GMVD's ROE is +2.09%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, GMVD is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check WRBY's competition here
GMVD vs HAE Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, HAE has a market cap of 2.9B. Regarding current trading prices, GMVD is priced at $0.18, while HAE trades at $60.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas HAE's P/E ratio is 16.86. In terms of profitability, GMVD's ROE is +2.09%, compared to HAE's ROE of +0.20%. Regarding short-term risk, GMVD is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check HAE's competition here
GMVD vs XRAY Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, XRAY has a market cap of 2.5B. Regarding current trading prices, GMVD is priced at $0.18, while XRAY trades at $12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas XRAY's P/E ratio is -2.85. In terms of profitability, GMVD's ROE is +2.09%, compared to XRAY's ROE of -0.48%. Regarding short-term risk, GMVD is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check XRAY's competition here
GMVD vs LMAT Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, LMAT has a market cap of 2.1B. Regarding current trading prices, GMVD is priced at $0.18, while LMAT trades at $91.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas LMAT's P/E ratio is 40.06. In terms of profitability, GMVD's ROE is +2.09%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, GMVD is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check LMAT's competition here
GMVD vs ATRC Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, GMVD is priced at $0.18, while ATRC trades at $31.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ATRC's P/E ratio is -53.41. In terms of profitability, GMVD's ROE is +2.09%, compared to ATRC's ROE of -0.02%. Regarding short-term risk, GMVD is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ATRC's competition here
GMVD vs KMTS Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, GMVD is priced at $0.18, while KMTS trades at $26.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas KMTS's P/E ratio is -6.51. In terms of profitability, GMVD's ROE is +2.09%, compared to KMTS's ROE of -1.89%. Regarding short-term risk, GMVD is more volatile compared to KMTS. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check KMTS's competition here
GMVD vs QDEL Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, QDEL has a market cap of 1.5B. Regarding current trading prices, GMVD is priced at $0.18, while QDEL trades at $21.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas QDEL's P/E ratio is -1.35. In terms of profitability, GMVD's ROE is +2.09%, compared to QDEL's ROE of -0.46%. Regarding short-term risk, GMVD is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check QDEL's competition here
GMVD vs PLSE Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, PLSE has a market cap of 1.5B. Regarding current trading prices, GMVD is priced at $0.18, while PLSE trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas PLSE's P/E ratio is -18.79. In terms of profitability, GMVD's ROE is +2.09%, compared to PLSE's ROE of -0.73%. Regarding short-term risk, GMVD is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check PLSE's competition here
GMVD vs AZTA Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, GMVD is priced at $0.18, while AZTA trades at $28.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas AZTA's P/E ratio is 50.48. In terms of profitability, GMVD's ROE is +2.09%, compared to AZTA's ROE of -0.03%. Regarding short-term risk, GMVD is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check AZTA's competition here
GMVD vs NVCR Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, NVCR has a market cap of 1.3B. Regarding current trading prices, GMVD is priced at $0.18, while NVCR trades at $11.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas NVCR's P/E ratio is -7.06. In terms of profitability, GMVD's ROE is +2.09%, compared to NVCR's ROE of -0.50%. Regarding short-term risk, GMVD is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check NVCR's competition here
GMVD vs BLFS Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, BLFS has a market cap of 1.1B. Regarding current trading prices, GMVD is priced at $0.18, while BLFS trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas BLFS's P/E ratio is -60.76. In terms of profitability, GMVD's ROE is +2.09%, compared to BLFS's ROE of -0.01%. Regarding short-term risk, GMVD is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check BLFS's competition here
GMVD vs NNNN Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, NNNN has a market cap of 1.1B. Regarding current trading prices, GMVD is priced at $0.18, while NNNN trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas NNNN's P/E ratio is 411.67. In terms of profitability, GMVD's ROE is +2.09%, compared to NNNN's ROE of +0.11%. Regarding short-term risk, GMVD is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check NNNN's competition here
GMVD vs STAA Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, STAA has a market cap of 876.7M. Regarding current trading prices, GMVD is priced at $0.18, while STAA trades at $18.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas STAA's P/E ratio is -9.06. In terms of profitability, GMVD's ROE is +2.09%, compared to STAA's ROE of -0.27%. Regarding short-term risk, GMVD is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check STAA's competition here
GMVD vs ATRI Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, GMVD is priced at $0.18, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ATRI's P/E ratio is 64.50. In terms of profitability, GMVD's ROE is +2.09%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, GMVD is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ATRI's competition here
GMVD vs ANGO Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ANGO has a market cap of 462.5M. Regarding current trading prices, GMVD is priced at $0.18, while ANGO trades at $11.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ANGO's P/E ratio is -16.75. In terms of profitability, GMVD's ROE is +2.09%, compared to ANGO's ROE of -0.15%. Regarding short-term risk, GMVD is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ANGO's competition here
GMVD vs KRMD Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, KRMD has a market cap of 219.6M. Regarding current trading prices, GMVD is priced at $0.18, while KRMD trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas KRMD's P/E ratio is -59.25. In terms of profitability, GMVD's ROE is +2.09%, compared to KRMD's ROE of -0.22%. Regarding short-term risk, GMVD is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check KRMD's competition here
GMVD vs UTMD Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, UTMD has a market cap of 217.3M. Regarding current trading prices, GMVD is priced at $0.18, while UTMD trades at $66.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas UTMD's P/E ratio is 19.49. In terms of profitability, GMVD's ROE is +2.09%, compared to UTMD's ROE of +0.10%. Regarding short-term risk, GMVD is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check UTMD's competition here
GMVD vs OSUR Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, OSUR has a market cap of 201.1M. Regarding current trading prices, GMVD is priced at $0.18, while OSUR trades at $2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas OSUR's P/E ratio is -3.40. In terms of profitability, GMVD's ROE is +2.09%, compared to OSUR's ROE of -0.16%. Regarding short-term risk, GMVD is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check OSUR's competition here
GMVD vs STXS Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, STXS has a market cap of 192.7M. Regarding current trading prices, GMVD is priced at $0.18, while STXS trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas STXS's P/E ratio is -7.12. In terms of profitability, GMVD's ROE is +2.09%, compared to STXS's ROE of -2.49%. Regarding short-term risk, GMVD is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check STXS's competition here
GMVD vs SMTI Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, SMTI has a market cap of 182.7M. Regarding current trading prices, GMVD is priced at $0.18, while SMTI trades at $20.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas SMTI's P/E ratio is -28.40. In terms of profitability, GMVD's ROE is +2.09%, compared to SMTI's ROE of -1.28%. Regarding short-term risk, GMVD is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check SMTI's competition here
GMVD vs NYXH Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, NYXH has a market cap of 172.2M. Regarding current trading prices, GMVD is priced at $0.18, while NYXH trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas NYXH's P/E ratio is -1.73. In terms of profitability, GMVD's ROE is +2.09%, compared to NYXH's ROE of -1.01%. Regarding short-term risk, GMVD is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check NYXH's competition here
GMVD vs INFU Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, INFU has a market cap of 161.4M. Regarding current trading prices, GMVD is priced at $0.18, while INFU trades at $7.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas INFU's P/E ratio is 30.52. In terms of profitability, GMVD's ROE is +2.09%, compared to INFU's ROE of +0.10%. Regarding short-term risk, GMVD is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check INFU's competition here
GMVD vs PDEX Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, PDEX has a market cap of 128.9M. Regarding current trading prices, GMVD is priced at $0.18, while PDEX trades at $40.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas PDEX's P/E ratio is 11.59. In terms of profitability, GMVD's ROE is +2.09%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, GMVD is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check PDEX's competition here
GMVD vs MBOT Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, MBOT has a market cap of 93.9M. Regarding current trading prices, GMVD is priced at $0.18, while MBOT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas MBOT's P/E ratio is -4.58. In terms of profitability, GMVD's ROE is +2.09%, compared to MBOT's ROE of -0.37%. Regarding short-term risk, GMVD is more volatile compared to MBOT. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check MBOT's competition here
GMVD vs AKYA Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, GMVD is priced at $0.18, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas AKYA's P/E ratio is -1.34. In terms of profitability, GMVD's ROE is +2.09%, compared to AKYA's ROE of -6.72%. Regarding short-term risk, GMVD is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check AKYA's competition here
GMVD vs ZTEK Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ZTEK has a market cap of 63.1M. Regarding current trading prices, GMVD is priced at $0.18, while ZTEK trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ZTEK's P/E ratio is -8.40. In terms of profitability, GMVD's ROE is +2.09%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, GMVD is more volatile compared to ZTEK. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ZTEK's competition here
GMVD vs DXR Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, DXR has a market cap of 61.5M. Regarding current trading prices, GMVD is priced at $0.18, while DXR trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas DXR's P/E ratio is 76.31. In terms of profitability, GMVD's ROE is +2.09%, compared to DXR's ROE of +0.05%. Regarding short-term risk, GMVD is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check DXR's competition here
GMVD vs STSS Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, STSS has a market cap of 52.2M. Regarding current trading prices, GMVD is priced at $0.18, while STSS trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas STSS's P/E ratio is N/A. In terms of profitability, GMVD's ROE is +2.09%, compared to STSS's ROE of -0.91%. Regarding short-term risk, GMVD is more volatile compared to STSS. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check STSS's competition here
GMVD vs OMIC Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, GMVD is priced at $0.18, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas OMIC's P/E ratio is -0.58. In terms of profitability, GMVD's ROE is +2.09%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, GMVD is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check OMIC's competition here
GMVD vs IGAP Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, GMVD is priced at $0.18, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas IGAP's P/E ratio is -10.52. In terms of profitability, GMVD's ROE is +2.09%, compared to IGAP's ROE of +1.21%. Regarding short-term risk, GMVD is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check IGAP's competition here
GMVD vs NEPH Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, NEPH has a market cap of 43.4M. Regarding current trading prices, GMVD is priced at $0.18, while NEPH trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas NEPH's P/E ratio is 29.14. In terms of profitability, GMVD's ROE is +2.09%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, GMVD is more volatile compared to NEPH. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check NEPH's competition here
GMVD vs POCI Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, POCI has a market cap of 34.2M. Regarding current trading prices, GMVD is priced at $0.18, while POCI trades at $4.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas POCI's P/E ratio is -5.21. In terms of profitability, GMVD's ROE is +2.09%, compared to POCI's ROE of -0.61%. Regarding short-term risk, GMVD is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check POCI's competition here
GMVD vs EKSO Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, EKSO has a market cap of 29.3M. Regarding current trading prices, GMVD is priced at $0.18, while EKSO trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas EKSO's P/E ratio is -2.08. In terms of profitability, GMVD's ROE is +2.09%, compared to EKSO's ROE of -0.91%. Regarding short-term risk, GMVD is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check EKSO's competition here
GMVD vs SDC Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, GMVD is priced at $0.18, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas SDC's P/E ratio is -0.03. In terms of profitability, GMVD's ROE is +2.09%, compared to SDC's ROE of -1.96%. Regarding short-term risk, GMVD is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for GMVD.Check SDC's competition here
GMVD vs HBIO Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, HBIO has a market cap of 26.1M. Regarding current trading prices, GMVD is priced at $0.18, while HBIO trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas HBIO's P/E ratio is -0.48. In terms of profitability, GMVD's ROE is +2.09%, compared to HBIO's ROE of -1.99%. Regarding short-term risk, GMVD is more volatile compared to HBIO. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check HBIO's competition here
GMVD vs IVC Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, GMVD is priced at $0.18, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas IVC's P/E ratio is -0.79. In terms of profitability, GMVD's ROE is +2.09%, compared to IVC's ROE of -0.46%. Regarding short-term risk, GMVD is more volatile compared to IVC. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check IVC's competition here
GMVD vs ZJYL Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ZJYL has a market cap of 22.9M. Regarding current trading prices, GMVD is priced at $0.18, while ZJYL trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ZJYL's P/E ratio is 14.63. In terms of profitability, GMVD's ROE is +2.09%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, GMVD is more volatile compared to ZJYL. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ZJYL's competition here
GMVD vs MLSS Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, MLSS has a market cap of 20.3M. Regarding current trading prices, GMVD is priced at $0.18, while MLSS trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas MLSS's P/E ratio is -2.86. In terms of profitability, GMVD's ROE is +2.09%, compared to MLSS's ROE of -1.65%. Regarding short-term risk, GMVD is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check MLSS's competition here
GMVD vs RVP Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, RVP has a market cap of 20.1M. Regarding current trading prices, GMVD is priced at $0.18, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas RVP's P/E ratio is -3.05. In terms of profitability, GMVD's ROE is +2.09%, compared to RVP's ROE of -0.08%. Regarding short-term risk, GMVD is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check RVP's competition here
GMVD vs RGNT Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, RGNT has a market cap of 16.1M. Regarding current trading prices, GMVD is priced at $0.18, while RGNT trades at $3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas RGNT's P/E ratio is -3.71. In terms of profitability, GMVD's ROE is +2.09%, compared to RGNT's ROE of N/A. Regarding short-term risk, GMVD is more volatile compared to RGNT. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check RGNT's competition here
GMVD vs FEMY Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, FEMY has a market cap of 15.9M. Regarding current trading prices, GMVD is priced at $0.18, while FEMY trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas FEMY's P/E ratio is -0.78. In terms of profitability, GMVD's ROE is +2.09%, compared to FEMY's ROE of -7.64%. Regarding short-term risk, GMVD is more volatile compared to FEMY. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check FEMY's competition here
GMVD vs NXGL Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, NXGL has a market cap of 12.9M. Regarding current trading prices, GMVD is priced at $0.18, while NXGL trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas NXGL's P/E ratio is -3.36. In terms of profitability, GMVD's ROE is +2.09%, compared to NXGL's ROE of -0.55%. Regarding short-term risk, GMVD is more volatile compared to NXGL. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check NXGL's competition here
GMVD vs NXGLW Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, NXGLW has a market cap of 8.6M. Regarding current trading prices, GMVD is priced at $0.18, while NXGLW trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas NXGLW's P/E ratio is -0.08. In terms of profitability, GMVD's ROE is +2.09%, compared to NXGLW's ROE of -0.55%. Regarding short-term risk, GMVD is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for GMVD.Check NXGLW's competition here
GMVD vs LUCY Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, LUCY has a market cap of 5.1M. Regarding current trading prices, GMVD is priced at $0.18, while LUCY trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas LUCY's P/E ratio is -0.55. In terms of profitability, GMVD's ROE is +2.09%, compared to LUCY's ROE of -0.00%. Regarding short-term risk, GMVD is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check LUCY's competition here
GMVD vs NSTG Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, GMVD is priced at $0.18, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas NSTG's P/E ratio is -0.03. In terms of profitability, GMVD's ROE is +2.09%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, GMVD is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for GMVD.Check NSTG's competition here
GMVD vs MHUA Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, MHUA has a market cap of 3.2M. Regarding current trading prices, GMVD is priced at $0.18, while MHUA trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas MHUA's P/E ratio is 0.32. In terms of profitability, GMVD's ROE is +2.09%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, GMVD is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check MHUA's competition here
GMVD vs GMVDW Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, GMVD is priced at $0.18, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas GMVDW's P/E ratio is N/A. In terms of profitability, GMVD's ROE is +2.09%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, GMVD is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for GMVD.Check GMVDW's competition here
GMVD vs POAI Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, POAI has a market cap of 1.7M. Regarding current trading prices, GMVD is priced at $0.18, while POAI trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas POAI's P/E ratio is -0.02. In terms of profitability, GMVD's ROE is +2.09%, compared to POAI's ROE of +4.25%. Regarding short-term risk, GMVD is more volatile compared to POAI. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check POAI's competition here
GMVD vs AVGR Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, GMVD is priced at $0.18, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas AVGR's P/E ratio is -0.05. In terms of profitability, GMVD's ROE is +2.09%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, GMVD is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for GMVD.Check AVGR's competition here
GMVD vs GCTK Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, GCTK has a market cap of 868.2K. Regarding current trading prices, GMVD is priced at $0.18, while GCTK trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas GCTK's P/E ratio is N/A. In terms of profitability, GMVD's ROE is +2.09%, compared to GCTK's ROE of -26.59%. Regarding short-term risk, GMVD is more volatile compared to GCTK. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check GCTK's competition here
GMVD vs LUCYW Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, LUCYW has a market cap of 320.5K. Regarding current trading prices, GMVD is priced at $0.18, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas LUCYW's P/E ratio is N/A. In terms of profitability, GMVD's ROE is +2.09%, compared to LUCYW's ROE of -0.00%. Regarding short-term risk, GMVD is more volatile compared to LUCYW. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check LUCYW's competition here
GMVD vs WOK Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, WOK has a market cap of 8.1K. Regarding current trading prices, GMVD is priced at $0.18, while WOK trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas WOK's P/E ratio is N/A. In terms of profitability, GMVD's ROE is +2.09%, compared to WOK's ROE of -0.07%. Regarding short-term risk, GMVD is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check WOK's competition here
GMVD vs IIN Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, IIN has a market cap of 0. Regarding current trading prices, GMVD is priced at $0.18, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas IIN's P/E ratio is 226.45. In terms of profitability, GMVD's ROE is +2.09%, compared to IIN's ROE of -0.00%. Regarding short-term risk, GMVD is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check IIN's competition here
GMVD vs HRC Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, HRC has a market cap of 0. Regarding current trading prices, GMVD is priced at $0.18, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas HRC's P/E ratio is 41.92. In terms of profitability, GMVD's ROE is +2.09%, compared to HRC's ROE of +0.14%. Regarding short-term risk, GMVD is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check HRC's competition here
GMVD vs APR Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, APR has a market cap of 0. Regarding current trading prices, GMVD is priced at $0.18, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas APR's P/E ratio is 22.59. In terms of profitability, GMVD's ROE is +2.09%, compared to APR's ROE of +9.81%. Regarding short-term risk, GMVD is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check APR's competition here
GMVD vs ATRS Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, GMVD is priced at $0.18, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ATRS's P/E ratio is 14.95. In terms of profitability, GMVD's ROE is +2.09%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, GMVD is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ATRS's competition here
GMVD vs ARTC Comparison February 2026
GMVD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMVD stands at 1.8M. In comparison, ARTC has a market cap of 0. Regarding current trading prices, GMVD is priced at $0.18, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMVD currently has a P/E ratio of -0.01, whereas ARTC's P/E ratio is N/A. In terms of profitability, GMVD's ROE is +2.09%, compared to ARTC's ROE of N/A. Regarding short-term risk, GMVD is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for GMVD.Check ARTC's competition here